RxDoctor Payments Data

David Maron, MD

Cardiovascular Disease · Stanford, CANPI 1538251962

Payments from drug & device makers

$532,805in general payments, 2019–2025

Across 69 payments — averaging $7721.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cleerly, Inc.$408K
  • Genentech, Inc.$99K
  • AstraZeneca$8K
  • Heartflow, Inc.$7K
  • Bayer Healthcare LLC$4K
  • Regeneron$3K
  • plus $5K from 5 others

What the payments were for

  • Consulting fees$18,27984%
  • Travel & lodging$3502%
  • Food & beverage$3,03714%
  • Education$520%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cleerly, Inc.22$407,973
Genentech, Inc.26$98,542
AstraZeneca4$7,544
Heartflow, Inc.3$6,600
Bayer Healthcare LLC2$3,505
Regeneron6$3,313
Abiomed2$2,750
Scilex Pharmaceuticals Inc.1$2,400
Merck1$125
Idorsia Pharmaceuticals US Inc1$52
Ablative Solutions, Inc.1$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$532,805 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$35,958
Medicare patients
279
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab86$79,692
EliquisApixaban22$37,069
JardianceEmpagliflozin13$19,517
Praluent PenAlirocumab13$7,279
Rosuvastatin Calcium147$3,190
Ezetimibe114$3,052
Colchicine16$1,523
Atorvastatin Calcium86$1,002
Carvedilol34$661
Metoprolol Succinate51$645
Amlodipine Besylate91$560
ClopidogrelClopidogrel Bisulfate22$315
Lisinopril33$244
Chlorthalidone12$212
Nitroglycerin20$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Colchicine$2,400$1,52316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →